Major histocompatibility complex class II, DR beta 1 chain (HLA-DRB1)

Major histocompatibility complex class II, DR beta 1 chain (HLA-DRB1) is the principal beta chain of the HLA-DR antigen-presenting molecule found on professional antigen-presenting cells such as B lymphocytes, dendritic cells, and macrophages. Together with the alpha chain (HLA-DRA), this transmembrane protein forms a heterodimer that presents processed peptides to CD4+ T lymphocytes, thereby playing a central role in adaptive immune responses and self/nonself discrimination[1][4][6][7]. HLA-DRB1 is highly polymorphic, with distinct alleles conferring differential susceptibilities to autoimmune disease and influencing outcomes in infectious diseases and transplantation. The specific peptide (autoantigenic or pathogenic) presented by the HLA-DRB1*04 molecular variant is implicated in the initiation or propagation of autoimmune responses in conditions such as rheumatoid arthritis[1][4]. MHC class II molecules are quintessential receptors for immunological surveillance but are not traditional therapeutic targets; experimental and indirect targeting approaches are being explored for immune modulation and cancer immunotherapy[1][2][4].

Other names

HLA-DRB1HLA class II histocompatibility antigen, DRB1 beta chainMHC class II DRB1DR beta 1

Drugs or biologics influencing peptide loading or antigen presentation modify T cell activation, influencing immune responses, but no direct HLA-DRB1 modulators are in clinical use. Indirect action via regulation of antigen presentation, immune checkpoint inhibition, or immunomodulation (by influencing APC activity or T cell responsiveness).